Uti treatment
Reading File
Finding Sources
Searching PubMed
"urinary tract infection" AND treatment
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive information to write a thorough UTI treatment summary. Let me compile the full answer.
UTI Treatment
Overview
Urinary tract infections (UTIs) are classified as uncomplicated (healthy, non-pregnant women with lower tract symptoms) or complicated (men, pregnancy, structural/functional abnormalities, hospital-acquired, catheter-associated, or upper tract involvement). Treatment depends on this classification, local resistance patterns, and patient factors.
1. Uncomplicated Cystitis (Adult Women)
These are first-line agents per IDSA/ESCMID guidelines:
| Drug | Dose & Duration | Notes |
|---|---|---|
| Nitrofurantoin (macrocrystals/monohydrate) | 100 mg twice daily x 5 days | Preferred; resistance rate ~6% for ESBL E. coli |
| TMP-SMX (DS) | 160/800 mg twice daily x 3 days | Avoid if local resistance >20% |
| Fosfomycin | 3 g single oral dose | Resistance rate only ~2%; convenient |
| Pivmecillinam | 400 mg twice daily x 5 days | Not available in the US |
| Fluoroquinolones (ciprofloxacin, levofloxacin) | 3 days | Not first-line - reserve due to resistance and adverse effects (tendon rupture, QT prolongation) |
| Beta-lactams (amoxicillin-clavulanate) | 5-7 days | Less effective than other options; not first-line |
Fluoroquinolones should not be used as first-line agents for uncomplicated UTI per IDSA guidelines - ROSEN's Emergency Medicine confirms this - because of increased resistance. - Tintinalli's Emergency Medicine, p. 623
2. Pyelonephritis & Complicated UTI
Outpatient (Stable Patient)
- Ciprofloxacin 500 mg orally twice daily x 7 days - first-line if local quinolone resistance <10%
- TMP-SMX DS twice daily x 14 days - only if organism known to be susceptible
- If quinolone resistance >10%: give a single dose of ceftriaxone 1 g IV, then switch to oral agent guided by culture
Inpatient (Empiric IV Therapy)
Per Tintinalli's Emergency Medicine (Table 91-6):
| Agent | Dose |
|---|---|
| Ciprofloxacin | 400 mg IV every 12 h |
| Ceftriaxone | 1-2 g IV once daily |
| Cefotaxime | 1-2 g IV every 8 h |
| Gentamicin/tobramycin | 3 mg/kg/d ± ampicillin 2 g every 6 h |
| Piperacillin-tazobactam | 3.375 g IV every 6 h |
| Cefepime | 1-2 g IV every 8 h |
| Ertapenem | 1 g IV once daily |
| Meropenem | 1 g IV every 8 h |
Duration: 7-14 days for most cases. Men may do well with 7 days. Sepsis from UTI may need 21 days.
After clinical improvement on IV antibiotics, step down to oral therapy guided by culture results. - Tintinalli's Emergency Medicine, p. 624
3. Special Populations
Pregnancy
- Safe: beta-lactams, nitrofurantoin, metronidazole, clindamycin, fosfomycin
- Avoid: fluoroquinolones, tetracyclines
- Treat even asymptomatic bacteriuria in pregnancy (can progress to pyelonephritis)
Men
- All UTIs in men should be considered potentially complicated
- Treat for at least 7 days; evaluate for prostate involvement
- Rule out prostatitis, which requires longer treatment (fluoroquinolone x 4-6 weeks if confirmed)
Recurrent UTI (>2 episodes/6 months or >3/year)
- Treat the acute episode with a standard short course
- Prophylaxis options:
- Continuous low-dose daily antibiotic (e.g., TMP-SMX, nitrofurantoin)
- Postcoital single dose (if coitus-associated)
- Patient-initiated self-treatment at symptom onset
- Counsel on discontinuation of spermicidal contraception if used - Tintinalli's Emergency Medicine, p. 624
Catheter-Associated UTI (CAUTI)
- Replace or remove catheter before starting antibiotics
- Treat symptomatic CAUTI with 7 days (5 days if prompt resolution)
- Asymptomatic bacteriuria in catheterized patients does not require antibiotics
4. Key Resistance Points
- ESBL-producing E. coli: use nitrofurantoin (6% resistance) or fosfomycin (3% resistance)
- TMP-SMX: rates exceed 20% in western/southern US - use cautiously
- Fluoroquinolone resistance is rising - treat as non-first-line empirically
5. Symptomatic Relief
- Phenazopyridine 200 mg three times daily for 1-2 days provides urinary analgesia (turns urine orange; not an antibiotic)
- Adequate hydration is helpful
Recent Evidence (2024)
A 2024 WikiGuidelines consensus statement (PMID 39495518) covering both pediatric and adult UTI was published in JAMA Network Open, largely reinforcing nitrofurantoin, TMP-SMX, and fosfomycin as first-line agents for uncomplicated UTI while reserving fluoroquinolones for complicated cases. A 2024 systematic review (PMID 37986168) also supports methenamine hippurate as a prophylactic option for recurrent UTI, with a favorable side-effect profile compared to continuous antibiotics.
Sources: Tintinalli's Emergency Medicine (9th ed.) | Goldman-Cecil Medicine | ROSEN's Emergency Medicine | Brenner & Rector's The Kidney | Comprehensive Clinical Nephrology (7th ed.)
Protocal for stroke
Reading File
Finding Sources
Searching PubMed
"ischemic stroke" AND "management" AND "guideline"
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive data to produce a detailed stroke protocol. Let me compile the full answer.
Stroke Protocol
Quick Classification: Ischemic vs. Hemorrhagic
Before any treatment, a non-contrast CT head is mandatory to differentiate:
- Ischemic stroke (~85%) - eligible for thrombolysis and/or thrombectomy
- Hemorrhagic stroke (~15%) - thrombolytics are absolutely contraindicated
PART 1 - Acute Ischemic Stroke
Step 1: Immediate Assessment (Door to Decision: <10-15 min)
- Activate stroke team / code stroke immediately on arrival
- NIHSS score - quantify neurological deficit
- Last known well (LKW) time - this defines the treatment window
- Vital signs, O2 saturation, IV access, cardiac monitoring
- Labs: CBC, BMP, coagulation (PT/INR/PTT), glucose, type & screen
- 12-lead ECG (detect AF or MI as cause)
- Non-contrast CT head - door to CT ideally <25 min
Key general measures:
-
O2 only if saturation <94% (routine supplemental O2 not indicated)
-
Correct hypoglycemia before thrombolytics (glucose <50 mg/dL is a contraindication)
-
Correct dehydration with IV crystalloid, but do not volume-overload
-
Treat fever with acetaminophen; identify the source
-
Admit to stroke unit - reduces complications, length of stay, and long-term disability
-
Tintinalli's Emergency Medicine, p. 619-621
Step 2: IV Thrombolysis (tPA/Alteplase)
The AHA/ASA 2018 criteria (Table below) govern eligibility.
IV Alteplase Dose
- 0.9 mg/kg IV (max 90 mg)
- 10% as IV bolus over 1 minute
- Remaining 90% as infusion over 60 minutes
- Door to needle goal: <60 minutes
Inclusion Criteria
| Criterion | Detail |
|---|---|
| Symptom onset <3 hours | Or 3-4.5 hours with additional criteria (see below) |
| Age ≥18 years | No upper age limit for <3-hour window |
| Measurable neurological deficit on NIHSS | No lower limit - even mild disabling deficits may qualify |
| CT without hemorrhage | Required |
3 to 4.5 Hour Window - Additional requirements:
- Age >60 years, OR no history of both diabetes AND prior stroke
- NIHSS ≤25
- No brain imaging showing ischemia >1/3 of MCA territory
Key Exclusion Criteria
| Contraindication |
|---|
| Intracranial hemorrhage (current or prior history) |
| Symptoms/signs of subarachnoid hemorrhage |
| CT showing extensive hypoperfusion (>1/3 MCA territory) |
| BP >185/110 mm Hg despite treatment |
| Platelet count <100,000/mm³ |
| INR >1.7 or aPTT >40 sec or PT >15 sec |
| Glucose <50 mg/dL (treat first) |
| Major surgery or head trauma within 3 months |
| Intracranial or intraspinal surgery within 21 months |
| GI/GU bleed within 3 months |
| Suspected aortic arch dissection |
| Intracranial neoplasm |
Note on tenecteplase: Doses of 0.25 mg/kg have shown comparable results to alteplase in several trials and may offer improved recanalization before thrombectomy - gaining acceptance as an alternative. - Adams and Victor's Principles of Neurology, 12th ed.
Step 3: Blood Pressure Management
Before tPA / awaiting thrombectomy:
| Target | Agents |
|---|---|
| SBP ≤185 mmHg, DBP ≤110 mmHg | Labetalol 10-20 mg IV over 1-2 min (may repeat x1) |
| Nicardipine infusion 5 mg/h, titrate up by 2.5 mg/h q 5-15 min (max 15 mg/h) | |
| Clevidipine infusion 1-2 mg/h, double every 2-5 min (max 21 mg/h) | |
| Hydralazine or enalaprilat as alternatives |
- If BP target cannot be achieved, patient is no longer a tPA candidate
- After tPA, maintain BP <180/105 mmHg for 24 hours
Without tPA (not eligible for reperfusion):
-
Do NOT treat hypertension unless BP >220/120 mmHg
-
If treatment needed, reduce BP by ~15% gradually over the first 24 hours
-
Avoid rapid BP reduction - cerebral perfusion is BP-dependent in acute ischemic stroke
-
Sodium nitroprusside and other NO-donors should be avoided (raise intracranial pressure)
-
Tintinalli's Emergency Medicine, p. 622; ROSEN's Emergency Medicine
Step 4: Endovascular Mechanical Thrombectomy (EVT)
Indicated for large vessel occlusion (LVO) - MCA, ICA, basilar artery.
Criteria (per AHA guidelines):
- Onset to treatment up to 24 hours (with favorable imaging selection in 6-24 hour window)
- Modified Rankin Scale pre-stroke ≤1 (independent)
- NIHSS ≥6 (significant deficit)
- ASPECTS ≥6 on CT (limited core infarct)
- CT/MR angiography confirming proximal LVO
Key points:
- tPA can be given first if eligible ("bridging therapy"), then proceed to thrombectomy
- tPA achieves recanalization in only ~20% of LVO; EVT success rates are much higher
- For basilar artery occlusion, EVT can be life-saving even with longer time windows
- Door to puncture goal: <90 minutes
A 2025 meta-analysis (PMID 40245349) confirmed that EVT also benefits patients with large ischemic core strokes (ASPECTS 0-5), with improved functional outcomes compared to medical therapy alone.
- Tintinalli's Emergency Medicine; Bradley and Daroff's Neurology; Harrison's Principles of Internal Medicine 22E
PART 2 - Hemorrhagic Stroke (Intracerebral Hemorrhage)
Key Differences from Ischemic Stroke
| Feature | Ischemic | Hemorrhagic |
|---|---|---|
| tPA | Indicated (if eligible) | Absolutely contraindicated |
| BP target | Permissive (no treatment <220/120) | Aggressive - target SBP 140 mmHg |
| Antiplatelets | Start within 24-48 hours | Contraindicated acutely |
BP Management in ICH
- If SBP 150-220 mmHg: reduce to 140 mmHg (improves functional outcomes)
- If SBP >220 mmHg: rapid reduction via continuous IV agents (nicardipine, labetalol, clevidipine)
- Target reduction to SBP 140 mmHg within 1 hour of diagnosis (INTERACT2 data)
General ICH Management
-
Reverse anticoagulation urgently (vitamin K + FFP/PCC for warfarin; specific reversal agents for DOACs)
-
Control ICP if elevated (head elevation 30°, avoid hypotonic fluids, mannitol/hypertonic saline)
-
Neurosurgical consultation - especially for cerebellar hemorrhage, hydrocephalus, or deteriorating patient
-
30-day mortality approaches 50%
-
ROSEN's Emergency Medicine; Bradley and Daroff's Neurology
PART 3 - Secondary Prevention (After Acute Phase)
| Stroke Type | Agent |
|---|---|
| Non-cardioembolic ischemic stroke | Aspirin 325 mg then 81 mg daily |
| Dual antiplatelet (TIA/minor stroke) | Aspirin + clopidogrel x 21 days, then single agent |
| Cardioembolic (atrial fibrillation) | Oral anticoagulation (DOAC preferred over warfarin) |
| Cryptogenic (ESUS) | Antiplatelet therapy; anticoagulation trials inconclusive |
| Carotid stenosis >70% | Carotid endarterectomy within 2 weeks |
| Hypertension | Strict BP control is the single most important risk factor modification |
| Hyperlipidemia | High-intensity statin; LDL target <70 mg/dL (or <55 for high-risk) |
A 2026 ILEP consensus (PMID 41249078) recommends intensive lipid lowering for both primary and secondary stroke prevention, with aggressive LDL targets.
PART 4 - Stroke Mimics to Exclude
Before committing to tPA, consider mimics that can look like stroke:
- Hypoglycemia (always check glucose first)
- Todd's paralysis (post-seizure deficit)
- Hemiplegic migraine
- Hypertensive encephalopathy
- Brain tumor with acute decompensation
- MS relapse
- Conversion disorder
Summary Timeline ("Time is Brain")
| Milestone | Target Time |
|---|---|
| Door to physician | <10 min |
| Door to CT scan | <25 min |
| Door to CT interpretation | <45 min |
| Door to tPA needle | <60 min |
| Door to arterial puncture (EVT) | <90 min |
Every 1 minute of LVO = ~1.9 million neurons lost.
Sources: Tintinalli's Emergency Medicine (9th ed.) | ROSEN's Emergency Medicine | Bradley and Daroff's Neurology in Clinical Practice | Adams and Victor's Principles of Neurology (12th ed.) | Harrison's Principles of Internal Medicine (22nd ed.) | Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.